Skin and Connective Tissue Diseases Clinical Trial
Official title:
Biomarker for Hyaline Fibromatosis Syndrome - An International, Multicenter, Epidemiological Protocol
Development of a new MS-based biomarker for the early and sensitive diagnosis of Hyaline fibromatosis syndrome from the blood
Hyaline fibromatosis syndrome (HFS) is rare autosomal recessive disease characterized by the deposition of amorphous hyaline material in skin and visceral organs. It represents a disease spectrum with infantile systemic hyalinosis (ISH) being the severe form and juvenile hyaline fibromatosis (JHF) being the mild form. Dermatologic manifestations include thickened skin, perianal nodules, and facial papules, gingival hyperplasia, large subcutaneous tumors on the scalp, hyperpigmented plaques over the metacarpophalangeal joints and malleoli, and joint contractures. ISH shows a severe visceral involvement, recurrent infections, and early death. The lesions appear as pearly papules or fleshy nodules. The severity is variable. Some individuals present in infancy and have additional visceral or systemic involvement, which can lead to early death. These patients may show intractable diarrhea and increased susceptibility to infection. Other patients have later onset of a milder disorder affecting only the face and digits. Additional features include gingival hypertrophy, progressive joint contractures resulting in severe limitation of mobility, osteopenia, and osteoporosis. Histologic analysis of skin lesions shows proliferation of spindle-shaped cells forming strands in a homogeneous and hyaline eosinophilic extracellular material in the dermis. New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
| Active, not recruiting |
NCT05525741 -
Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients
|
N/A | |
| Completed |
NCT02379793 -
Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects
|
Phase 1 | |
| Completed |
NCT01093911 -
Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
| Completed |
NCT00147511 -
Time To Efficacy and Onset Of Action Of Linezolid
|
Phase 4 | |
| Completed |
NCT02355639 -
A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
|
Phase 1 | |
| Completed |
NCT01764594 -
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
|
Phase 1 | |
| Active, not recruiting |
NCT05185258 -
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
|
Phase 4 | |
| Completed |
NCT02985437 -
Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin
|
Phase 1 | |
| Completed |
NCT02518048 -
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
|
Phase 2 | |
| Completed |
NCT02416258 -
A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
|
Phase 2 |